An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

Background: Treatment of localised renal cell carcinoma consists of partial or radical nephrectomy. A substantial proportion of patients are at risk for recurrence because no effective adjuvant therapy exists. We investigated the use of an autologous, tumour-derived heat-shock protein (glycoprotein 96)-peptide complex (HSPPC-96; vitespen) as adjuvant treatment in patients at high risk of recurrence after resection of locally advanced renal cell carcinoma.

The choice of urinary drainage in patients with ureteral calculi of solitary kidneys.

Purpose: To evaluate the safety and efficacy of the treatment of patients with ureteral calculi of solitary kidneys (UCSK) in relation to the modality of urinary drainage.

Materials And Methods: We have studied a total of 55 patients with UCSK during the period from 1999 to 2002, 15 of them (27.3%) with radio-opaque calculi (ROC).